Five-year OLYMPUS data show Jelmyto (UGN-101) sustains kidney-sparing control in low-grade UTUC, with most responders remaining event-free.
|Videos|September 23, 2020
A 74-Year-Old Man With Diffuse Large B-Cell Lymphoma
Author(s)Gilles Salles, MD, PhD
Gilles Salles, MD, reviews the case of a 74-year-old man with diffuse large B-cell lymphoma.
Advertisement
Case: A 74-Year-Old Man with Diffuse Large B-Cell Lymphoma
Initial Presentation
- A 74-year-old man presented with fever, 14-lb unintentional weight loss and occasional chest pain
- PMH: DM, medically controlled
- PE: tired-appearing man; palpable bilateral cervical lymphadenopathy
Clinical Work-up
- Labs: LDH 2 times above normal; Hb 10.8 g/dL; bilirubin 2.3 mg/dL; creatinine 1.7 mg/fl; all others WNL
- Hepatitis B, C and HIV negative
- Lymph node biopsy; CD 20+ confirmed DLBCL; IHC panel: CD 10+, CD 19+
- Imaging:
- Whole body PET/CT scan showed activity the cervical lymph node region, largest node 2.5 cm; evidence of axillary and thoracic subcutaneous tissue involvement
- Ann Arbor stage 4; IPI: high-risk; ECOG PS 1
Treatment
- Treatment initiated with R-CHOP + RT; well-tolerated
- Interim PET scan after 4 cycles; progressive diseases noted
- Due to transplant ineligibility patient was treated with tafasitamab + lenalidomide
Advertisement
Related to this article
New study shows CT-measured body fat, not BMI, links obesity to higher lung cancer risk via immune T-cell changes—hinting at prevention through weight loss.
The IMpactMF trial was discontinued after an independent committee determined imetelstat was unlikely to improve overall survival.
The EGFR x LGR5 bispecific antibody petosemtamab demonstrated improved overall survival and overall response rate when added to pembrolizumab in head and neck squamous cell carcinoma.
COA urges Supreme Court review of Mississippi 340B contract pharmacy law, spotlighting PBM influence, drug access concerns, and calls for tighter oversight.
New Name, Same Connection to Care
LITESPARK-012 data at ESMO 2026 show that adding belzutifan or quavonlimab to pembrolizumab/lenvatinib did not improve survival for advanced kidney cancer.
Updated survival findings, perioperative treatment strategies, and circulating tumor DNA analyses highlight evolving approaches to genitourinary cancers.
Advertisement
Advertisement
Trending on Targeted Onc
1
ESMO 2026: ADCs and New Combinations Advance Lung Cancer Care
2
Novel ADCs Show Responses in Ovarian and Cervical Cancer at ESMO 2026
3
340B Contract Pharmacy Case Rekindles Scrutiny Over Program Intent
4
ESMO 2026: New Data Advance Prostate, Kidney, and Bladder Cancer Care
5